# GoodRx

Type: Company (GDRX)

Source: GetYourBrief — https://getyourbrief.com/entity/goodrx
Canonical HTML page: https://getyourbrief.com/entity/goodrx

## Timeline

- **2026-02-26**: Q4 2025 Earnings — Payoneer reports Q4 results, missing estimates but providing 2026 guidance.
- **2026-02-24**: Bank Charter Application — Company files for a U.S. national bank charter with the OCC.
- **2026-02-17**: Stablecoin Integration — Payoneer adds stablecoin capabilities for cross-border business payments.

## Recent coverage (7 stories, network-wide)

### Payoneer Pivots to Banking and Stablecoins Amid Q4 Earnings Miss
2026-02-26 22:39:45 · Sector: saas · Sentiment: Neutral · Impact: 5/10 · Sources: 12

Payoneer Global Inc. reported Q4 2025 results that missed analyst expectations on both revenue and earnings, triggering a cautious market reaction. Despite the miss, the company signaled a major strategic shift by applying for a U.S. national bank charter and expanding into stablecoin-based cross-border settlements.
Full story: https://getsaasbrief.com/story/payoneer-q4-2025-earnings-bank-charter-stablecoins

### Payoneer Pivots Upmarket: Q4 Earnings Miss Tempered by 2026 Growth Targets
2026-02-26 22:39:10 · Sector: startups · Sentiment: Neutral · Impact: 5/10 · Sources: 12

Payoneer missed top and bottom-line estimates for Q4 2025, triggering a stock decline despite a 12% core revenue growth forecast for 2026. The company is aggressively shifting focus toward larger SMBs, stablecoin integration, and a U.S. national bank charter to solidify its cross-border payment dominance.
Full story: https://getstartupbrief.com/story/payoneer-q4-2025-earnings-analysis-fintech-pivot

### Payoneer Leads Mid-Cap Earnings Surge as B2B Resilience Offsets Macro Volatility
2026-02-26 22:38:34 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 12

Payoneer reported robust Q4 2025 results, driven by double-digit growth in B2B volume and strategic expansion into emerging markets. The broader mid-cap landscape shows a divergence between high-growth consumer brands like Celsius and R&D-heavy biotech firms navigating a complex regulatory environment.
Full story: https://getfinancebrief.com/story/payoneer-q4-2025-earnings-analysis

### Q4 2025 Biotech Earnings: CRISPR and Radiopharma Lead Growth
2026-02-26 22:32:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 12

The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
Full story: https://getbiobrief.com/story/q4-2025-biotech-earnings-analysis

### Mid-Cap Biotech Earnings: Specialized Platforms Outperform in Q4 2025
2026-02-26 22:32:06 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 12

The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Full story: https://gethealthbrief.com/story/mid-cap-biotech-q4-2025-earnings-intelligence

### AI-Driven Verticals: Schrödinger and GoodRx 2025 Results Signal Sector Maturity
2026-02-26 03:32:19 · Sector: ai · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Schrödinger and GoodRx reported full-year 2025 results, demonstrating the growing financial impact of AI-driven computational platforms in drug discovery and healthcare. These reports, alongside Churchill Downs' record performance, highlight a broader trend of data-centric companies leveraging machine learning to optimize specialized market verticals.
Full story: https://getaibrief.com/story/schrodinger-goodrx-churchill-downs-2025-earnings-analysis

### GoodRx and Schrödinger Report 2025 Results Amid Shifting Pharma Tech Landscape
2026-02-26 03:31:42 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3

GoodRx and Schrödinger released their full-year 2025 financial results, highlighting a critical period of transition for digital health and computational drug discovery. While GoodRx focused on stabilizing its prescription marketplace margins, Schrödinger demonstrated the growing scalability of its AI-driven software platform alongside its internal clinical pipeline.
Full story: https://getbiobrief.com/story/goodrx-schrodinger-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.